Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine with or without Lenalidomide or Vorinostat in MDS and CMML
NCT01522976Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2012
- Primary completion
- Jun 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of lenalidomide, vorinostat in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by National Cancer Institute. Started Mar 2012; status: active, not recruiting.
02
Drugs
lenalidomidevorinostat
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01522976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01522976.